多西他赛单药与培美曲塞联合顺铂二线治疗老年晚期胃癌的疗效及对患者生活质量的影响

目的:探讨多西他赛单药与培美曲塞联合顺铂二线治疗老年晚期胃癌的疗效及对患者生活质量的影响,为临床用药提供参考。方法:选取我院2014年6月-2017年6月期间收治的120例一线化疗失败的老年晚期胃癌患者,按照随机数字表法将患者分为观察组和对照组各60例,观察组使用培美曲塞联合顺铂治疗,对照组单独使用多西他赛治疗,两组均治疗3个疗程。治疗3个疗程后,采用实体肿瘤的疗效评价标准(RECIST)对两组患者的临床疗效进行评价,参照抗癌药物常见毒副反应分级标准统计患者出现的不良反应,采用生活质量量表评价患者的生活质量,并对所有患者进行为期半年的随访,统计两组患者的生存率。结果:观察组有效率(RR)为30.00%,略高于对照组的25.00%,但两组比较差异无统计学意义(P>0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。治疗后,观察组患者日常生活、社会活动、抑郁、焦虑得分均明显高于对照组(P<0.05)。观察组患者半年生存率为71.67%,明显高于对照组的48.33%(P<0.05)。结论:相比于多西他赛单药治疗,培美曲塞联合顺铂二线治疗老年晚期胃癌能够改善患者生活质量,延长其生存期,安全可靠。

Efficacy of Docetaxel and Pemetrexed Combined with Cisplatin as Second-line Therapy for Elderly Patients with Advanced Gastric Cancer and Its Effect on Quality of Life of Patients

ABSTRACT Objective: To investigate the efficacy of docetaxel and pemetrexed combined with cisplatin as second-line therapy for advanced gastric cancer in elderly patients and its effect on the quality of life of patients, so as to provide reference for clinical medication. Methods: 120 elderly patients with advanced gastric cancer who failed first-line chemotherapy in our hospital from June 2014 to June 2017 were selected. According to the random number table method, the patients were divided into observation group and control group with 60 cases each group. The observation group was treated with pemetrexed combined with cisplatin, while the control group was treated with docetaxel alone, the two groups were treated for 3 courses. After 3 courses of treatment, the clinical efficacy of the two groups was evaluated by evaluation criteria for therapeutic efficacy of solid tumors (RECIST). According to the classification standard of common toxicity and side effects of anticancer drugs, the adverse reactions of patients in the course of treatment were counted. Quality of life scale was used to evaluate the quality of life of patients after treatment, the patients were followed up for half a year, and the survival rates of the two groups were counted. Results: The effective rate (RR) of the observation group was 30.00%, which was slightly higher than that of the control group (25.00%), but there was no significant difference between the two groups (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). After treatment, the scores of daily life, social activities, depression and anxiety in the observation group were significantly higher than those in the control group (P<0.05). The half-year survival rate in the observation group was 71.67%, which was significantly higher than 48.33% in the control group (P<0.05). Conclusion: Compared with docetaxel monotherapy, pemetrexed combined with cisplatin second-line treatment of elderly patients with advanced gastric cancer can improve the quality of life, prolong their survival, it is safe and reliable.